

**Renalytix plc**  
**("Renalytix" or the "Company")**

**Directorate Change**  
*Julian Baines MBE appointed as Executive Chairman*

**LONDON and NEW YORK, 5 November 2024** - Renalytix plc (LSE: REXX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution passed at the Company's General Meeting on 31 October 2024. Julian replaces Christopher Mills who will move to a Non-Executive Director role.

Julian has significant experience in the life science industry and was the CEO of EKF Diagnostics Holdings Plc (**EKF**) and BBI Holdings plc. Julian rejoined the executive team at EKF as Executive Chairman in February 2023. Julian is also currently Non-Executive Chairman of Verici Dx plc. Before joining EKF, he undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. Julian was previously Non-Executive Chairman of Renalytix from March 2018 to June 2020.



**Julian Baines MBE**  
**Executive Chairman of Renalytix PLC**

**James McCullough, CEO of Renalytix plc, commented:** "I am delighted to welcome Julian back to the Board of Renalytix. Julian has a wealth of knowledge in the sector and significant experience with AIM listed healthcare companies which will be paramount toward supporting the commercial success of our business. Most importantly, I would like to thank Christopher for his continuing contribution to Renalytix. It is a pleasure to work alongside him, and his leadership as Chairman has been invaluable."

**Additional Disclosures Required under the AIM Rules for Companies**

Julian Huw Baines (aged 60) has held the following directorship or partnerships in the past five years:

**Current directorships/partnerships**

Verici Dx PLC  
EKF Diagnostics Holdings PLC  
J & K (Cardiff) Limited

**Previous directorships/partnerships (last five years)**

Intuitive Investments Group PLC  
Trellus Health PLC  
EKF Molecular Diagnostics Limited  
Quotient Diagnostics Limited  
360 Genomics Limited  
EKF Diagnostics Limited  
Renalytix PLC

*Julian Baines was a director of BB Electronics Limited, which went into liquidation in 1991 with a creditor shortfall of approximately £400,000. He was also a director of Calibre Communications Limited, which went into liquidation in 1991 with a creditor shortfall of approximately £20,000. Julian Baines was not the subject of public criticism by the liquidator in connection with the liquidations.*

*Julian Baines and persons closely associated (as defined under MAR) with Mr Baines currently hold 1,801,711 ordinary shares of £0.0025 each in the Company.*

*Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.*

**For further information, please contact:**

**Renalytix plc**  
James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)  
Via Walbrook PR

**Stifel (Nominated Adviser and Joint Broker)**  
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

**Oberon Capital (Joint Broker)**  
Mike Seabrook / Nick Lovering

Tel: 020 3179 5300

**Walbrook PR Limited**  
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07407 804 654

**CapComm Partners**  
Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)

**About Renalytix**

Renalytix (LSE: REX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAUSOARSOUARUA